RT Journal Article
T1 Innate Immune Receptors, Key Actors in Cardiovascular Diseases.
A1 Jaén, Rafael I
A1 Val-Blasco, Almudena
A1 Prieto, Patricia
A1 Gil-Fernández, Marta
A1 Smani, Tarik
A1 López-Sendón, José Luis
A1 Delgado, Carmen
A1 Boscá, Lisardo
A1 Fernández-Velasco, María
K1 AMI, acute myocardial infarction
K1 CARD, caspase activation and recruitment domain
K1 CVD, cardiovascular disease
K1 Ca2+, calcium ion
K1 DAMPs, danger-associated molecular patterns
K1 DAP, D-glutamyl-meso-diaminopimelic acid
K1 ER, endoplasmic reticulum
K1 HF, heart failure
K1 I/R, ischemia/reperfusion
K1 IL, interleukin
K1 MAPK, mitogen-activated protein kinase
K1 NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells
K1 NLR, nucleotide-binding oligomerization domain-like receptors
K1 NLRP, nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain-containing receptor
K1 NLRP3
K1 NOD, Nucleotide-binding oligomerization domain-containing protein
K1 NOD1
K1 PAMP, pathogen-associated molecular pattern
K1 ROS, reactive oxygen species
K1 SR, sarcoplasmic reticulum
K1 TLR, toll-like receptor
K1 cardiovascular disease
K1 innate immune system
K1 nucleotide-binding oligomerization domain-like receptors
K1 toll-like receptors
AB Cardiovascular diseases (CVDs) are the leading cause of death in the industrialized world. Most CVDs are associated with increased inflammation that arises mainly from innate immune system activation related to cardiac damage. Sustained activation of the innate immune system frequently results in maladaptive inflammatory responses that promote cardiovascular dysfunction and remodeling. Much research has focused on determining whether some mediators of the innate immune system are potential targets for CVD therapy. The innate immune system has specific receptors-termed pattern recognition receptors (PRRs)-that not only recognize pathogen-associated molecular patterns, but also sense danger-associated molecular signals. Activation of PRRs triggers the inflammatory response in different physiological systems, including the cardiovascular system. The classic PRRs, toll-like receptors (TLRs), and the more recently discovered nucleotide-binding oligomerization domain-like receptors (NLRs), have been recently proposed as key partners in the progression of several CVDs (e.g., atherosclerosis and heart failure). The present review discusses the key findings related to the involvement of TLRs and NLRs in the progression of several vascular and cardiac diseases, with a focus on whether some NLR subtypes (nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain-containing receptor 3 and nucleotide-binding oligomerization domain-containing protein 1) can be candidates for the development of new therapeutic strategies for several CVDs.
YR 2020
FD 2020-07-27
LK https://hdl.handle.net/10668/26653
UL https://hdl.handle.net/10668/26653
LA en
DS RISalud
RD Apr 6, 2025